购物车
全部删除
您的购物车当前为空
别名 恩西地平, AG-221
Enasidenib (AG-221) 是口服具有活力的、可逆的、选择性IDH2突变酶抑制剂,抑制IDH2R140Q 和 IDH2R172K 的IC50分别为100 和 400 nM。

Enasidenib (AG-221) 是口服具有活力的、可逆的、选择性IDH2突变酶抑制剂,抑制IDH2R140Q 和 IDH2R172K 的IC50分别为100 和 400 nM。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 243 | 现货 | |
| 2 mg | ¥ 339 | 现货 | |
| 5 mg | ¥ 529 | 现货 | |
| 10 mg | ¥ 763 | 现货 | |
| 25 mg | ¥ 1,370 | 现货 | |
| 50 mg | ¥ 2,320 | 现货 | |
| 100 mg | ¥ 3,490 | 现货 | |
| 200 mg | ¥ 4,970 | 现货 | |
| 500 mg | ¥ 7,580 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 593 | 现货 |
Enasidenib 相关产品
| 产品描述 | Enasidenib (AG-221) is an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. |
| 靶点活性 | IDH2 (R172K):400 nM, IDH2 (R140Q):100nM |
| 体外活性 | 该化合物经验证可将2-HG水平降低超过90%,并在体外逆转组蛋白和脱氧核糖核酸(DNA)的高甲基化,同时在白血病细胞模型中诱导分化[2]。 |
| 体内活性 | Enasidenib能有效减少移植小鼠骨髓、血浆和尿液中的2HG含量。Enasidenib治疗能恢复由突变IDH2表达抑制的巨核细胞-红系前体(MEP)分化,并可逆转突变IDH2在突变干/前体细胞中对DNA甲基化的影响。因此,结合IDH2抑制剂和其他针对AML(急性髓性白血病)的靶向治疗进行临床试验,以提高治疗效果是有必要的[1]。 |
| 激酶实验 | Untranslated region-mediated luciferase reporter expression: HEK293 cells are transfected with a GEMS reporter vector that contains the luciferase open-reading frame flanked by and under post-transcriptional control of the BMI-1 5′ and 3′ UTRs. The resulting stable cells (F8) are treated with PTC-209 or vehicle control overnight, and then luciferase reporter activity is determined using Bright-Glo assays. The assays are run in triplicate for each point, and the percentage of inhibition was calculated against vehicle control. |
| 别名 | 恩西地平, AG-221 |
| 分子量 | 473.38 |
| 分子式 | C19H17F6N7O |
| CAS No. | 1446502-11-9 |
| Smiles | CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F |
| 密度 | 1.477 g/cm3 (Predicted) |
| 颜色 | White |
| 物理性状 | Solid |
| 存储 | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | H2O: < 1 mg/mL (insoluble or slightly soluble) Ethanol: 100 mg/mL (211.25 mM), Sonication is recommended. DMSO: 245 mg/mL (517.55 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (10.56 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容